Navigation Links
SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray
Date:7/1/2008

Strategic Pharmaceutical Advisors (SRxA) and Sinol USA, Inc. announced the signing of a Memorandum of Understanding signifying their intent to enter into a marketing agreement for SINOL Nasal Spray, an all natural, capsaicin-based product for fast relief from allergy and sinus congestion and headaches of all types.

Washington, DC, and Newtown, CT (PRWEB) July 1, 2008 -- Strategic Pharmaceutical Advisors (SRxA) and Sinol USA, Inc., announced today the signing of a Memorandum of Understanding signifying their intent to enter into a marketing agreement for SINOL Nasal Spray. Under the proposed terms of the agreement SRxA will lead the worldwide educational and information support of SINOL Nasal Spray to professional and consumer audiences.

Headquartered in Newtown Connecticut, Sinol USA Inc. is a healthcare company dedicated to the Development of products using all natural ingredients. Available without a prescription, SINOL Nasal Spray formulations use clean, old fashioned ingredients for fast relief from allergy and sinus congestion and headaches of all degrees and types.

SRxA is a health education and strategic planning firm with world-renowned physicians as its partners and advisors. As part of this agreement, SRxA will develop programming tailored to the education of professional and consumer audiences and deliver it in a variety of media appropriate for each target audiences. Strategic Pharmaceutical Advisors is headquartered in Washington, DC, with offices in London and Hong Kong.

In announcing this collaboration, Paul Carpenter, Chief Executive Officer of Sinol USA, Inc. noted, "SINOL Nasal Sprays have caught the attention of U.S. medical practitioners in a very short period of time. With this collaboration, we now look forward to expanding our US base and reaching an international physician audience through the proven expertise and global sphere of influence of Strategic Pharmaceutical Advisors."

Dr. Christos S. Efessiou, Strategic Pharmaceutical Advisors' Chief Executive Officer, commented "The option of providing the public with an all natural, non-prescription alternative for relief from allergy-related congestion and headaches, impressed our Team enough to seek an active partnership in SINOL. My colleagues and I are excited at the possibilities that this partnership will offer to healthcare professionals and to allergy and headache sufferers."

Sinol USA is presently working with Strategic BioSciences, a SRxA affiliate, in a pioneering new product reformulation agreement which is expected to offer significant advantages to SINOL users. The two companies expect to announce this agreement in the near future.

For more information please visit: www.SRxA.com and www.sinolusa.com.

# # #


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
2. Honour Healthcare and River Logic Deliver Comprehensive Integrated Business Planning Solution Through Strategic Alliance
3. American Well and Microsoft Enter Into a Strategic Collaboration to Bring Healthcare to Peoples Homes
4. StayWell Custom Communications Announces Strategic Alliance With HealthMedia
5. TetraQ and Q-Pharm form strategic alliance
6. Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
7. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
8. Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform
9. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
10. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
11. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: